このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Acarix 将来の成長

Future 基準チェック /26

Acarix収益と収益がそれぞれ年間102.7%と76.9%増加すると予測されています。

主要情報

102.7%

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	24.6%
収益成長率	76.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

OM:ACARIX - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	256	N/A	N/A	N/A	1
12/31/2025	177	2	-3	3	1
12/31/2024	54	-54	-52	-50	1
3/31/2024	6	-76	-79	-79	N/A
12/31/2023	6	-78	-81	-81	N/A
9/30/2023	7	-78	-77	-77	N/A
6/30/2023	6	-82	-82	-82	N/A
3/31/2023	6	-79	-80	-79	N/A
12/31/2022	6	-77	-75	-75	N/A
9/30/2022	5	-71	-70	-70	N/A
6/30/2022	5	-60	-59	-58	N/A
3/31/2022	4	-55	-55	-55	N/A
12/31/2021	4	-52	-48	-48	N/A
9/30/2021	4	-47	-47	-47	N/A
6/30/2021	3	-45	-44	-44	N/A
3/31/2021	3	-42	-37	-37	N/A
12/31/2020	2	-41	-37	-37	N/A
9/30/2020	2	-40	-32	-32	N/A
6/30/2020	1	-43	-37	-37	N/A
3/31/2020	2	-44	-40	-40	N/A
12/31/2019	2	-46	-45	-45	N/A
9/30/2019	1	-48	-45	-45	N/A
6/30/2019	2	-50	-45	-45	N/A
3/31/2019	1	-47	-42	-42	N/A
12/31/2018	1	-42	-39	-39	N/A
9/30/2018	1	-43	-36	-36	N/A
6/30/2018	1	-37	-32	-32	N/A
3/31/2018	1	-34	-35	-34	N/A
12/31/2017	1	-30	N/A	-41	N/A
9/30/2017	0	-32	N/A	-36	N/A
6/30/2017	0	-55	N/A	-33	N/A
3/31/2017	N/A	-50	N/A	-24	N/A
12/31/2016	N/A	-48	N/A	-9	N/A
9/30/2016	N/A	-35	N/A	-5	N/A
12/31/2015	N/A	-12	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACARIX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ACARIX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ACARIX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ACARIXの収益 ( 76.9% ) Swedish市場 ( 1.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ACARIXの収益 ( 76.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACARIXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Acarix 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 18% to kr0.90

Price target decreased to kr2.60

Recent updates

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

New 90-day low: kr1.12

Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study

Acarix Receives US Market Approval for the CADScor System

New 90-day high: kr1.29

Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR

Third quarter 2020 earnings released: kr0.11 loss per share

Acarix AB (publ) to Report Q1, 2021 Results on May 11, 2021

New 90-day high: kr1.22

Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million.

New 90-day low - kr0.73

Acarix AB (publ) to Report Q4, 2020 Results on Feb 18, 2021

Earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘